Live News Categoriesmarket

GALT.O (GALT.O) News

Follow GALT.O (GALT.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol GALT.O Asset market Sector Markets 90 days 1 Updated Oct 06, 2026, 12:11 PM UTC Open live news feed

M Galectin Therapeutics submits FDA registrational Phase 3 protocol for belapectin in MASH cirrhosis Galectin Therapeutics submitted a registrational Phase 3 protocol to the FDA for belapectin to prevent disease progression in MASH cirrhosis with portal hypertension. EQUITY | Oct 06, 2026, 12:11 PM UTC